Revive Therapeutics (CSE: RVV) this morning announced that on the heels of receiving FDA approval for phase 3 clinical trials of Bucillamine in the treatment of COVID-19, it currently intends to begin the clinical trials in September. The company is currently in the process of finalizing agreements and aligning resources to conduct the trials. Currently, … Continue reading Revive Announces Timeline For Phase 3 Studies, Sees Beneficial Psilocybin Developments